N6-methyladenosine binding protein YTHDF2 inhibits gastric cancer cell growth and predicts better prognosis in patients with gastric cancer

IF 5 2区医学 Q2 Medicine

Translational Oncology Pub Date : 2025-04-11 DOI:10.1016/j.tranon.2025.102395

Jun Zheng , Yinhua Liang , Xin Xu , Jianpeng Zhou , Shuang Jiang , Jiwei Yu

{"title":"N6-methyladenosine binding protein YTHDF2 inhibits gastric cancer cell growth and predicts better prognosis in patients with gastric cancer","authors":"Jun Zheng , Yinhua Liang , Xin Xu , Jianpeng Zhou , Shuang Jiang , Jiwei Yu","doi":"10.1016/j.tranon.2025.102395","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The potential role of N6-methyladenosine (m6A) in cancer progression has received significant attention in the past few years. The purpose of this study aimed to evaluate the impact of YTH N6-methyladenosine RNA-binding protein 2 (YTHDF2) on patient prognosis and its potential role in gastric cancer.</div></div><div><h3>Methods</h3><div>A total of 305 patients with clinically informative gastric cancer were identified from The Cancer Genome Atlas (TCGA) dataset, and GSE29272 and GSE84437 were used as external validation. Different m6A modulators were analyzed using the Limma package; the Cox regression models were used to determine risk factors for overall survival (OS). A 1:1 propensity score matching (PSM) analysis was used to adjust for differences in baseline clinicopathological characteristics between the YTHDF2 low and high expression groups. The Cox regression analysis was then used to identify risk factors for OS. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were used to explore the potential role and function of YTHDF2 in gastric cancer. And the effects of YTHDF2 on the growth of gastric cancer cells were detected in vivo and in vitro.</div></div><div><h3>Results</h3><div>Nineteen m6A methylation regulators were expressed in gastric cancer tissues; YTHDF2 was associated with the prognosis of gastric cancer patients. The expression level of YTHDF2, patient age, and tumor stage were independent risk factors for OS. After PSM, YTHDF2 expression led to a relatively better prognosis and staging. Patients in stage IV had a significantly worse prognosis. The expression of YTHDF2 was associated with cancer-related functions and pathways in gastric cancer. We found that YTHDF2 has lower expression in gastric cancer cells and inhibits the growth of GC cells.</div></div><div><h3>Conclusions</h3><div>The high expression of YTHDF2 can predict a better prognosis of gastric cancer patients. YTHDF2 exerts a critical role in gastric cancer progression by inhibiting the growth of GC cells.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"56 ","pages":"Article 102395"},"PeriodicalIF":5.0000,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1936523325001263","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The potential role of N6-methyladenosine (m6A) in cancer progression has received significant attention in the past few years. The purpose of this study aimed to evaluate the impact of YTH N6-methyladenosine RNA-binding protein 2 (YTHDF2) on patient prognosis and its potential role in gastric cancer.

Methods

A total of 305 patients with clinically informative gastric cancer were identified from The Cancer Genome Atlas (TCGA) dataset, and GSE29272 and GSE84437 were used as external validation. Different m6A modulators were analyzed using the Limma package; the Cox regression models were used to determine risk factors for overall survival (OS). A 1:1 propensity score matching (PSM) analysis was used to adjust for differences in baseline clinicopathological characteristics between the YTHDF2 low and high expression groups. The Cox regression analysis was then used to identify risk factors for OS. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were used to explore the potential role and function of YTHDF2 in gastric cancer. And the effects of YTHDF2 on the growth of gastric cancer cells were detected in vivo and in vitro.

Results

Nineteen m6A methylation regulators were expressed in gastric cancer tissues; YTHDF2 was associated with the prognosis of gastric cancer patients. The expression level of YTHDF2, patient age, and tumor stage were independent risk factors for OS. After PSM, YTHDF2 expression led to a relatively better prognosis and staging. Patients in stage IV had a significantly worse prognosis. The expression of YTHDF2 was associated with cancer-related functions and pathways in gastric cancer. We found that YTHDF2 has lower expression in gastric cancer cells and inhibits the growth of GC cells.

Conclusions

The high expression of YTHDF2 can predict a better prognosis of gastric cancer patients. YTHDF2 exerts a critical role in gastric cancer progression by inhibiting the growth of GC cells.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational Oncology ONCOLOGY-

CiteScore

8.40

自引率

2.00%

发文量

314

审稿时长

54 days

期刊介绍： Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.